Funke-Chambour, Manuela; Azzola, Andrea; Adler, Dan; Barazzone-Argiroffo, Constance; Benden, Christian; Boehler, Annette; Bridevaux, Pierre-Olivier; Brutsche, Martin; Clarenbach, Christian F; Hostettler, Katrin; Kleiner-Finger, Rebekka; Nicod, Laurent P; Soccal, Paola M; Tamm, Michael; Geiser, Thomas; Lazor, Romain (2017). Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment. Respiration, 93(5), pp. 363-378. Karger 10.1159/000464332
|
Text
464332.pdf - Published Version Available under License Publisher holds Copyright. Download (281kB) | Preview |
Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the choice between available drugs, their use in particular subgroups and clinical situations, time of treatment onset, termination, combination or switch, or nonpharmacologic management. To guide Swiss respiratory physicians in this evolving field still characterized by numerous areas of uncertainty, the Swiss Working Group for interstitial and rare lung diseases of the Swiss Respiratory Society provides a position paper on the diagnosis and treatment of IPF.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology |
UniBE Contributor: |
Funke-Chambour, Manuela, Azzola, Andrea, Geiser, Thomas (A) |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0025-7931 |
Publisher: |
Karger |
Language: |
English |
Submitter: |
Rahel Holderegger |
Date Deposited: |
27 Nov 2017 07:50 |
Last Modified: |
29 Mar 2023 23:35 |
Publisher DOI: |
10.1159/000464332 |
PubMed ID: |
28343230 |
Additional Information: |
T. Geiser and R. Lazor share last authorship. |
BORIS DOI: |
10.7892/boris.106600 |
URI: |
https://boris.unibe.ch/id/eprint/106600 |
Actions (login required)
 |
Edit item |